Főoldal

The AGVICO project aims to revolutionise viticulture through technology. Our initiative will leverage advanced image recognition algorithms alongside an unparalleled gene analysis database that will add significant value and innovation to the sector. If you would like to help us to archieve our goals please feel free to fill our questionaire.

iBioScience Ltd. was present for the first time as a Silver Sponsor at the XIV Congress of the Hungarian Society of Human Genetics and Genomics

The field of human genetics and genomics is one of the most dynamically developing disciplines of modern science and research, where new discoveries and innovations are constantly appearing. This field is attracting special attention, In Hungary, too as evidenced by the 14th annual congress of the Hungarian Human Genetics and Genomics Society, held in Budapest from 14-16 September. iBioScience Ltd. was an important participant in the event, as this time it was a silver sponsor of the congress. The event allowed the participants to learn in detail about the latest technologies used by our company, our service portfolio and our achievements for the first time.

The journey is the destination! That is the motto of the eXtremeMan Nagyatád race.

This year, for the first time, iBioScience Ltd. and the adventurous team of the Centre for Genomics and Bioinformatics of the University of Pécs participated in this prestigious and unique long-distance triathlon race in Hungary, not only as sponsors but also as a relay team. Defying the harsh weather conditions, they successfully completed the 3.86 km swim, 180 km bike ride and 42.2 km marathon run.

Thanks to Dr Gyula Herr, chairman of the organising committee, for making it possible for us to participate in the race.

See you again next year!

Our management is committed to ensuring that the services and products we offer are of the highest quality. That is why we set out to implement the ISO 9001:2015 quality management system in our operational control and work processes at the end of 2021. We are pleased to inform our existing and future partners that we have successfully achieved our goal on 12.09.2022 and obtained the quality management certificate for the “Next generation sequencing based diagnostic and research support tests, molecular biological products and consumables distribution”. By implementing an ISO 9001 quality management system, we have defined and documented the work processes that guarantee the conformity of the services and products we provide. We are convinced that the main basis for the long-term development of our company is the good relationship we build with our partners. We are confident that the introduction of a quality management system will help to serve the needs of our partners at an even higher level.

The Chamber of Commerce and Industry of Pécs-Baranya awarded the Baranya County Innovation Award to our company this year.

The Pécs-based iBioScience Kft. was founded in 2019 by Károly Fehér to boost the local biotechnology industry. A big factor in her decision was that her son was diagnosed that year with type one diabetes, which, as far as we know today, is an incurable disease that requires regular medication and constant medical attention. The company has established a joint laboratory at the Szentágothai János Research Centre. Their mission is to provide genomics services to academic research groups and local companies in the biomedical field. With their state-of-the-art tools and globally unique diagnostic solutions, they have the answers to identify genetic abnormalities that cause hereditary and tumour diseases. In addition to this, when the COVID epidemic broke out, they were instrumental in speeding up COVID diagnostics in Southern Hungary by automating PCR testing.

Our company has been invited by Board President Szabolcs Rabb to participate in a mutually effective cooperation which helps the professional relations in the field of bioinformatics and the cooperative work of the companies.

iBioScience Ltd. aims to contribute to the siginificant professional work of the Advisory Board. In addition to the professional experience gained in the fields of IT and Bioinformatics, the employees of iBioScience Ltd. wish to encourage the research groups and professional bodies to apply the new generation sequencing methods by jointly conducting R&D projects. This can open new innovation perspectives in the future.

’Our mission is to stimulate scientific research in the field of biotechnology’
Attila Samu, Sales Manager

iBioScience Ltd. In close cooperation with the Szentágothai Research Center (University of Pécs) and the Department of Laboratory Medicine (Pécs University Clinical Center) iBioScience Ltd. is utilizing its technological capacities to join the fight against coronavirus with a self-developed PCR-based screening program in preparation for the phase of mass diseases caused by the virus.

Regular screening allows for continuous and effective work, providing a kind of preventive background for employers. And it is essential for employees to have this sense of security that the Employer can provide in the coming months by using an effective screening test.

Our goal is to make available a type of screening method to employers that, unlike rapid tests, determines the presence of viral genetic material in a sample. That way infection can be determined with 100% confidence without symptom onset.

’Next-generation sequencing technologies are revolutionizing biomedical research.
This really changes everything – it will help patients and their families alike.’
Károly Fehér, managing director

In close cooperation with the Szentágothai Research Center (University of Pécs), iBioScience Ltd. provides the Hungarian scientific community with the most modern next-generation sequencing technology and background expertise. . At the Research Center, the company supports the application of next-generation sequencing in research, technology development and diagnostics with instrumentation and specialists.

’Genomics holds an enormous opportunity because both rare diseases and cancer are closely linked to changes in the genome.

We expect great interest from Hungarian patients and their families who would take part in this pioneering project.

We plan to sequence 10,000 whole human genomes, determine the order of the building blocks of the hereditary material, that is, assess the participants’ genetic status.

The project will in fact focus on patients with rare diseases and their families, as well as cancer patients, but we also plan to conduct population genomics studies.

Our goal is a voluntary, consensual and ethical program that benefits patients. We are confident that we can facilitate scientific discoveries that will be able to kick-start a Hungarian genomics industry.

The management of the University and the Szentágothai Research Center attracted Hungarian professionals from abroad who set up, run and developed such institutes and research groups at renowned European biotechnology organizations.

An important milestone was to win two European Union and Hungarian joint funding which have enabled us not only to acquire and manage personnel but also to operate the required world-class research infrastructure.

The most important will be to make personalized, precision medicine even more widespread in Hungary which will yield results not only in research, but also in everyday diagnostics.’

Dr. Gyenesei Attila

Head of the Bioinformatics Research Group (Szentágothai Research Center)